Xbaren 300 Tablet SR

The sustained-release (SR) formulation ensures a controlled and prolonged drug release, facilitating stable plasma concentrations and enhancing patient compliance by reducing dosing frequency. Xbaren 300 is also utilized as adjunctive therapy in patients with epilepsy who do not achieve adequate seizure control with monotherapy. The medication is generally well tolerated; however, clinicians should monitor for potential adverse effects such as dizziness, somnolence, headache, nausea, hyponatremia, and hypersensitivity reactions.

Dose adjustments may be necessary in patients with renal or hepatic impairment. Caution is advised when used concomitantly with other central nervous system depressants or enzyme-inducing antiepileptic drugs. Regular follow-up and therapeutic drug monitoring are recommended to optimize efficacy and minimize toxicity. Xbaren 300 Tablet SR should be prescribed and administered under medical supervision, with adherence to recommended dosing guidelines to ensure safe and effective seizure management.